ReviewLung cancer management2026
Potential to improve early detection of lung cancer through expansion of focused and opportunistic screening approaches: a scoping review focusing on potential expansion of screening risk factors and adoption of artificial intelligence models.
Review in Lung cancer management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow-dose computerized tomography (LDCT) is the gold standard for lung cancer (LC) screening, but access is hindered by strict eligibility criteria and limited infrastructure in low/middle-income countries. A combination of approaches, including expanded screening eligibility criteria and artificial intelligence (AI), could improve detection of early LC in patients excluded by current screening criteria. AREAS COVERED: A scoping review was conducted (PubMed, Cochrane library, congresses) to explore two potentially complementary approaches to enhance LC screening. The first identified LC risk factors and their potential inclusion in expanded screening criteria, allowing more people at risk to become eligible for screening; the second examined studies involving AI-augmented imaging (CXR or LDCT) to improve workflow, triage, and opportunistic nodule detection. EXPERT OPINION/COMMENTARY: Several robustly evidenced risk factors for LC were identified that are not included in current screening programs; widening of eligibility criteria could be considered based on local risk profile but requires further research to demonstrate benefit. Opportunistic use of AI-tools to assess incidental chest images may identify patients with pulmonary nodules requiring further investigation but their role in population-level LC screening requires prospective validation in diverse healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.